Paclitaxel

Synonyms: Taxol

  • Product code:LS-1047
  • CAS No.:33069-62-4
  • Formula:C47H51NO14
  • Molecular weight:853.93 g/mol

Starting at $422.50

Grouped product items
Qty Packing unit Price SKU
250 mg
$422.50
LS-1047.0250
500 mg
$650.00
LS-1047.0500
1 g
$910.00
LS-1047.1000
2 g
$1,430.00
LS-1047.2000
description

Paclitaxel, discovered in 1967, is a mitotic inhibitor used in cancer chemotherapy. It is used to treat patients with lung, ovarian, breast, head and neck cancer, advanced forms of Kaposi's sarcoma, and is also used for the prevention of restenosis. Paclitaxel stabilizes microtubules and as a result, interferes with the normal breakdown of microtubules during cell division.

While offering substantial improvement in patient care, paclitaxel has been a relatively controversial drug. Side effects such as unusual bruising or bleeding, pain/redness/swelling at the injection site, change in normal bowel habits for more than two days, fever, chills, cough, sore throat, difficulty swallowing, dizziness, shortness of breath, severe exhaustion, skin rash, facial flushing, female infertility by ovarian damage and chest pain can occur.

Combination therapy is a new approach to take advantage of Paclitaxel’s anti-cancer properties and diminish its side effects. PGA (Poly(Glutamic Acid)) is an ideal carrier to be

loaded with Paclitaxel and corresponding drugs as published in the following examples:

The combination of anti-angiogenic therapy with cytotoxic one offers a promising therapeutic approach. A polyglutamic acid (PGA)-Paclitaxel-E-[c(RGDfK)2] conjugate has been developed.1,2 The combination of E-[c(RGDfK)2] with Paclitaxel in the same PGA mainchain enhanced the effects previously seen for PGA-PTX alone by utilizing: (i) the additional

active targeting to the avß3 integrin and (ii) its anti-angiogenic character. PGA-Paclitaxel-E-[c(RGDfK)2] displayed a potent anti-angiogenic therapy, revealed by several

well-established in vitro assays. Mice bearing orthotopic mammary tumors demonstrated preferential tumor accumulation of the RGD-bearing conjugate, leading to enhanced antitumor

efficacy and a marked decrease in toxicity compared with free Paclitaxel. 1,2

references

A. Eldar-Boock , K. Miller, J. Sanchis, R. Lupu, M.J.Vicent, R. Satchi-Fainaro. Biomaterials 2011; 132(15): 3862-74.

R. Satchi-Fainaro and M.J. Vicent; WO/2009/141826 .

Saville, M.W.; Lietzau, J.; Pluda, J.M.; Wilson, W.H.; Humphrey, R.W.; Feigel, E.; Steinberg, S.M.; Broder, S. et al. The Lancet 1995; 346(8966): 26-8.

doi:10.1016/S0140-6736(95)92654-2.

Ozcelik, Bulent; Turkyilmaz, Cagdas; Ozgun, Mahmut Tuncay; Serin, Ibrahim Serdar; Batukan, Cem; Ozdamar, Saim; Ozturk, Ahmet; Fertility and Sterility 2010; 93(5): 1609-14.

doi:10.1016/j.fertnstert.2009.02.054.

Bulk or large quantity order?

Do you need larger quantities for your development or production?

Do you need further information about this product?

get in contact

Quick contact

Please send me more information about

We found other products you might like!